Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
S-1 · 1 trial · 1 indication
The best overall response rate is defined as the percentage of participants having achieved confirmed complete response plus partial response as the best overall response according to radiological assessments (based on Response Evaluation Criteria in Solid Tumors version 1.0 \[RECIST v 1.0\] criteria).
| Arm | Type | Description |
|---|---|---|
| Cetuximab plus cisplatin plus S-1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cetuximab | DRUG | Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent. |
| Cisplatin | DRUG | Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent |
| S-1 | DRUG | S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent. |
Inclusion Criteria: * Written informed consent and agreement with medically accepted contraception (in participants with conception potential) are obtained * Japanese participants aged greater than or equal to 20 years * Histologically confirmed adenocarcinoma of the stomach or GEJ (adenocarcinomas...
Top 20 of 45 competitors
S-1 is an investigational small molecule being studied for the treatment of gastric cancer. It is being evaluated in combination with other agents as a potential therapy for this indication. The drug is currently in clinical development and has not been approved for use.
S-1 is being developed by Merck KGaA, a company traded under the ticker MKGAF. The drug is an investigational small molecule in Phase 2 clinical development for gastric cancer.
S-1 is in Phase 2 clinical development. It has completed one Phase 2 trial for gastric cancer, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities.
S-1 has been studied in a completed Phase 2 clinical trial with the identifier NCT01388790. This trial, titled "Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer," enrolled 40 participants in Germany and evaluated the drug in patients with gastric cancer.
S-1 is the drug name used in clinical development by Merck KGaA. No alternative names have been reported for this investigational agent in the context of its gastric cancer program.